Panelists discuss how subcutaneous immune checkpoint inhibitors transform cancer care delivery by streamlining clinical workflows through faster administration in alternative care settings, improving patient quality of life by reducing treatment time and allowing greater flexibility in scheduling, and expanding access through home-based programs that serve rural and underserved populations while maintaining comprehensive monitoring and support systems.
Panelists discuss how IV administration of immune checkpoint inhibitors creates operational challenges, including infusion chair bottlenecks, complex scheduling, venous access difficulties, and time burdens for patients, while subcutaneous formulations offer potential solutions through simplified delivery, reduced infusion center strain, and improved patient convenience.
Taylor M. Weis, PharmD, BCOP, discusses NCCN guidelines for first-line therapy as well as the rationale behind the rapid change in treatment concepts for CLL.
Kirollos S. Hanna, PharmD, BCPS, BCOP, provides an overview of the shifts in treatments, trends, and outcomes seen over the past decade in CLL.
Published: September 30th 2025 | Updated:
